The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - A decision analysis

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 8, 2007, Pages 1147-1161

  Huang, E ^d   Esrailian, E ^a,b,d   Spiegel, B M R ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTITOL; LACTULOSE; NEOMYCIN; PROTON PUMP INHIBITOR; RIFAXIMIN;

ARTICLE; BUDGET; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE COURSE; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; FOLLOW UP; HEALTH CARE UTILIZATION; HEPATIC ENCEPHALOPATHY; HUMAN; INCIDENCE; LACTOSE INTOLERANCE; LIVER CIRRHOSIS; MEDICAL DECISION MAKING; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

COST-BENEFIT ANALYSIS; FEMALE; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMANS; LACTULOSE; LIVER FAILURE; LIVER TRANSPLANTATION; LOS ANGELES; MALE; MIDDLE AGED; RIFAMYCINS;

EID: 34748888352     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03464.x     Document Type: Article

References (98)

1. HCUP Nationwide Inpatient Sample (NIS), Agency for Healthcare Research and Quality (AHRQ), 2003. Available at.
2. Yoneyama K, Nebashi Y, Kiuchi Y, Shibata M, Mitamura K. Prognostic index of cirrhotic patients with hepatic encephalopathy with and without hepatocellular carcinoma. Dig Dis Sci 2004 49 : 1174 80.
3. Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004 40 : 823 30.
4. Groeneweg M, Quero JC, De Bruijn I, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998 28 : 45 9.
5. Li YY, Nie YQ, Sha WH, et al. Prevalence of subclinical hepatic encephalopathy in cirrhotic patients in China. World J Gastroenterol 2004 10 : 2397 401.
6. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, Garcia E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001 96 : 2718 23.
7. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001 16 : 531 5.
8. Marottoli RA, Cooney LM Jr., Wagner R, Doucette J, Tinetti ME. Predictors of automobile crashes and moving violations among elderly drivers. Ann Intern Med 1994 121 : 842 6.
9. Cordoba J, Lucke R. Driving under the influence of minimal hepatic encephalopathy. Hepatology 2004 39 : 599 601.
10. Wein C, Koch H, Popp B, Oehler G, Schauder P. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004 39 : 739 45.
11. Watanabe A, Tuchida T, Yata Y, Kuwabara Y. Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability. Metab Brain Dis 1995 10 : 239 48.
12. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev (Online) 2004 CD003044.
13. Strauss E, Tramote R, Silva EP, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992 39 : 542 5.
14. Venturini AP, Marchi E. In vitro and in vivo evaluation of L/105, a new topical intestinal rifamycin. Chemioterapia 1986 5 : 257 62.
15. Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995 49 : 467 84.
16. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005 51 (Suppl. 1 36 66.
17. Paik YH, Lee KS, Han KH, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005 46 : 399 407.
18. Giacomo F, Francesco A, Michele N, Oronzo S, Antonella F. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 1993 4 : 57 66.
19. Massa P, Vallerino E, Dodero M. Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose. Eur J Clin Res 1993 4 : 7 18.
20. Festi D, Mazzella G, Orsini M, et al. Rifaximin in the treatment of chronic hepatic encephalopathy; results of a multicenter study of efficacy and safety. Curr Ther Res 1993 54 : 598 609.
21. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993 13 : 109 18.
22. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000 12 : 203 8.
23. Fleming T. 2006 Red Book. Montvale, NJ : Thompson Medical Economics, 2006.
24. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol 2001 96 : 1968 76.
25. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005 42 : 1208 36.
26. Carithers RL Jr. Liver transplantation. American Association for the Study of Liver Diseases. Liver Transpl 2000 6 : 122 35.
27. Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 1997 92 : 1081 91.
28. Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004 39 : 841 56.
29. Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005 41 : 1407 32.
30. United Network for Organ Sharing. Available at http://www.UNOS.org, accessed on December 2006.
31. Gold MR, Siegel JE, Russell LB, Weinstein MG. Cost-effectiveness in Health and Medicine. New York, NY : Oxford University Press, 1996.
32. Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003 98 : 630 8.
33. Kanwal F, Farid M, Martin P, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006 101 : 2076 89.
34. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005 142 : 821 31.
35. Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004 127 : 1329 37.
36. Spiegel BM, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology 2002 122 : 1270 85.
37. Harris RA, Kuppermann M, Richter JE. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Am J Gastroenterol 1997 92 : 2179 87.
38. West DS, Johnson JT, Hong SH. A 30-month evaluation of the effects on the cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan. J Manag Care Pharm 2006 12 : 25 32.
39. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. PharmacoEconomics 2001 19 : 609 21.
40. Mauskopf JA, Earnshaw SR, Mullins C. Budget impact analysis: review of the state of the art. Expert Rev Pharmacoeconomics Outcomes Res 2005 5 : 65 79.
41. Dufour MC. Chronic liver disease and cirrhosis. In : Everhart JE, ed. Digestive Diseases in the United States: Epidemiology and Impact, Washington, DC : US Dept of Health and Human Services: NIH publication, 1994 : 615 45.
42. American Medical Association. AMA CPT Code Book. Chicago : American Medical Association, 2006.
43. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997 127 : 855 65.
44. United States Department of Labor Bureau of Labor Statistics. Consumer Price Index Calculator. Available at: http://www.bls.gov, accessed on December 2006.
45. Meunnig P. Designing and Conducting Cost-Effectivenss Analyses in Medicine and Health Care. San Francisco : Jossey-Bass, 2002.
46. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002 23 : 377 401.
47. Spiegel BMR, Lim B, Mann N, Dulai GS, Gralnek IM. The cost-effectiveness of intravenous versus oral proton pump inhibitor therapy in the management of peptic ulcer hemorrhage: a cost-effectiveness analysis. Clin Gastroenterol Hepatol 2006 4 : 988 97.
48. Pharmacy Benefit Report Facts and Figures. East Hanover, NJ : Novartis Pharmaceuticals, 2003.
49. Cooke CE, Wong W, Lee H. Utilization and cost of sildenafil in a large managed care organization with a quantity limit on sildenafil. J Manag Care Pharm 2005 11 : 674 80.
50. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C. Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol 2003 49 : 53 62.
51. Di Piazza S, Gabriella Filippazzo M, Valenza LM, et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991 23 : 403 7.
52. Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991 23 : 175 8.
53. Spiegel BM, Targownik L, Dulai GS, Gralnek IM. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003 138 : 795 806.
54. Spiegel BM, Targownik L, Dulai GS, Karsan HA, Gralnek IM. Endoscopic screening for esophageal varices in cirrhosis: is it ever cost effective? Hepatology 2003 37 : 366 77.
55. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977 72 : 573 83.
56. Loguercio C, Del Vecchio Blanco C, Coltorti M. Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. J Int Med Res 1987 15 : 335 43.
57. Orlandi F, Freddara U, Candelaresi MT, et al. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci 1981 26 : 498 506.
58. Simmons F, Goldstein H, Boyle JD. A controlled clinical trial of lactulose in hepatic encephalopathy. Gastroenterology 1970 59 : 827 32.
59. Germain L, Frexinos J, Louis A, Ribet A. Double blind study of lactulose in 8 patients with chronic hepatic encephalopathy after portocaval shunt. Arch Fr Mal App Dig 1973 62 : 293 302.
60. Messner M, le Gall J, Toulouse P, Javaudin L, Delamaire D, Brissot P. Plasma ratio of branched chain/aromatic amino acids during treatment of chronic hepatic encephalopathy using lactulose/bromocriptine in a double blind procedure [abstract]. Liver 1982 2 : 312.
61. Fiaccadori F, Ghinelli F, Pedretti G, Pelosi G, Sacchini D, Zeneroli ML. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Ital J Gastroenterol 1985 17 : 5 10.
62. Loguercio C, Abbiati R, Rinaldi M, Romano A, Del Vecchio Blanco C, Coltorti M. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 1995 23 : 39 46.
63. Li Z, Zhang H, Hong Y. Clinical effect of lactulose in the treatment of subclinical hepatic encephalopathy. Zhongguo Zhong Xi Yi Jie He Za Zhi 1999 9 : 13 5.
64. Watanabe A, Sakai T, Sato S, et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997 26 : 1410 4.
65. Dhiman RK, Sawhney MS, Chawla YK, Das G, Ram S, Dilawari JB. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 2000 45 : 1549 52.
66. Morgan MY, Hawley KE, Stambuk D. Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study. J Hepatol 1987 4 : 236 44.
67. Riggio O, Balducci G, Ariosto F, et al. Lactitol in the treatment of chronic hepatic encephalopathy - a randomized cross-over comparison with lactulose. Hepatogastroenterology 1990 37 : 524 7.
68. Riggio O, Balducci G, Ariosto F, et al. Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt. Dig Dis Sci 1989 34 : 823 9.
69. Lanthier PL, Morgan MY. Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose. Gut 1985 26 : 415 20.
70. Pai CH, Huang YS, Jeng WC, Chan CY, Lee SD. Treatment of porto-systemic encephalopathy with lactitol versus lactulose: a randomized controlled study. Zhonghua Yi Xue Za Zhi (Taipei) 1995 55 : 31 6.
71. Morgan MY, Alonso M, Stanger LC. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study. J Hepatol 1989 8 : 208 17.
72. Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin 1997 13 : 593 601.
73. Testa R, Eftimiadi C, Sukkar GS, et al. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985 11 : 387 92.
74. Elkington SG, Floch MH, Conn HO. Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial. N Engl J Med 1969 281 : 408 12.
75. Rodgers JB Jr., Kiley JE, Balint JA. Comparison of results of long-term treatment of chronic hepatic encephalopathy with lactulose and sorbitol. Am J Gastroenterol 1973 60 : 459 65.
76. Heredia D, Teres J, Orteu N, Rodes J. Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy. J Hepatol 1988 7 : 106 10.
77. Tarao K, Ikeda T, Hayashi K, et al. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 1990 31 : 702 6.
78. Russo M, Galanti B, Nardiello S, Pizzella T, Ronga C, Guiusti G. Ribostamycin for the treatment of hepatic encephalopathy. Curr Ther Res Clin 1989 45 : 131 41.
79. Horsmans Y, Solbreux PM, Daenens C, Desager JP, Geubel AP. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment Pharmacol Ther 1997 11 : 165 70.
80. Nie YQ, Zeng Z, Li YY, Sha WH, Ping L, Dai SJ. Long-term efficacy of lactulose in patients with subclinical hepatic encephalopathy. Zhonghua Nei Ke Za Zhi (Chinese J Int Med) 2003 42 : 261 3.
81. Uribe M, Toledo H, Perez F, et al. Lactitol, a second-generation disaccharide for treatment of chronic portal-systemic encephalopathy. A double-blind, crossover, randomized clinical trial. Dig Dis Sci 1987 32 : 1345 53.
82. Salerno F, Moser P, Maggi A, Vitaliani G, Benetti G. Effects of long-term administration of low-dose lactitol in patients with cirrhosis but without overt encephalopathy. J Hepatol 1994 21 : 1092 6.
83. Puxeddu A, Quartini M, Massimetti A, Ferrieri A. Rifaximin in the treatment of chronic hepatic encephalopathy. Curr Med Res Opin 1995 13 : 274 81.
84. Parini P, Cipolla A, Massimo R, Salzetta A, Mazzella G, Roda E. Effect of rifaximin and paromomycin in the treatment of portal-systemic encephalopathy. Curr Ther Res 1992 52 : 34 29.
85. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003 38 : 51 8.
86. Quero JC, Hartmann IJ, Meulstee J, Hop WC, Schalm SW. The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis. Hepatology 1996 24 : 556 60.
87. Hartmann IJ, Groeneweg M, Quero JC, et al. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol 2000 95 : 2029 34.
88. D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986 31 : 468 75.
89. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002 36 : 263 70.
90. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004 53 : 744 9.
91. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995 21 : 77 82.
92. Gentilini P, Laffi G, La Villa G, et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol 1997 92 : 66 72.
93. Weissberg JI, Andres LL, Smith CI, et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984 101 : 613 6.
94. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001 34 : 306 13.
95. Sulaiman HA. The development of hepatocellular carcinoma from liver cirrhosis during a follow-up study. Gastroenterol Jpn 1989 24 : 567 72.
96. Viola LA, Barrison IG, Coleman JC, et al. Natural history of liver disease in chronic hepatitis B surface antigen carriers. Survey of 100 patients from Great Britain. Lancet 1981 2 : 1156 9.
97. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992 103 : 1630 5.
98. Di Marco V, Lo Iacono O, Camma C, et al. The long-term course of chronic hepatitis B. Hepatology 1999 30 : 257 64.